tetano
Editor, Senior Moderator
Trends Immunol
. 2022 Jan 14;S1471-4906(22)00023-0.
doi: 10.1016/j.it.2022.01.009. Online ahead of print.
Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
Shan Su[SUP] 1 [/SUP], Weihua Li[SUP] 2 [/SUP], Shibo Jiang[SUP] 3 [/SUP]
Affiliations
Abstract
The concurrent prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high MERS-CoV-like mortality rates. Therefore, we argue that there is an urgent need to develop pan-β-CoV vaccines that can target not only current SARS-CoV-2 variants of concern, but also future putative SARS-CoV-3- or MERS-CoV-2-like coronavirus.
. 2022 Jan 14;S1471-4906(22)00023-0.
doi: 10.1016/j.it.2022.01.009. Online ahead of print.
Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
Shan Su[SUP] 1 [/SUP], Weihua Li[SUP] 2 [/SUP], Shibo Jiang[SUP] 3 [/SUP]
Affiliations
- PMID: 35125310
- DOI: 10.1016/j.it.2022.01.009
Abstract
The concurrent prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome coronavirus (MERS-CoV) raises the concern for the emergence of potential new β-CoV clades via genetic recombination, bearing high SARS-CoV-2-like transmissibility and high MERS-CoV-like mortality rates. Therefore, we argue that there is an urgent need to develop pan-β-CoV vaccines that can target not only current SARS-CoV-2 variants of concern, but also future putative SARS-CoV-3- or MERS-CoV-2-like coronavirus.